Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

04. Mai 2022 10:30 ET | Quelle: Umoja Biopharma, Inc.

Umoja Biopharma Presents Data on its Synthetic Cytokine Receptor Platform at the International Society for Cell and Gene Therapy Annual Meeting 2022

SEATTLE, May 04, 2022 (GLOBE NEWSWIRE) -- Umoja Biopharma, Inc., an immuno-oncology company pioneering off-the-shelf, integrated therapeutics that reprogram immune cells in vivo for patients with...
03. Mai 2022 08:00 ET | Quelle: Umoja Biopharma, Inc.

Umoja Biopharma Announces Activation of First ENLIGHTen Phase 1 Trial Site in Study of UB-TT170, a TumorTag that Targets Folate Receptors to Mark Tumors for Clearance by CAR T Cells

SEATTLE, May 03, 2022 (GLOBE NEWSWIRE) -- Umoja Biopharma, Inc., an immuno-oncology company pioneering off-the-shelf, integrated therapeutics that reprogram immune cells in vivo for patients with...
02. Mai 2022 16:30 ET | Quelle: Umoja Biopharma, Inc.

Umoja Biopharma to Present at the American Society of Gene and Cell Therapy 25th Annual Meeting

SEATTLE, May 02, 2022 (GLOBE NEWSWIRE) -- Umoja Biopharma, Inc., an immuno-oncology company pioneering off-the-shelf, integrated therapeutics that reprogram immune cells in vivo for patients with...
08. April 2022 13:02 ET | Quelle: Umoja Biopharma, Inc.

Umoja Biopharma Presents Data on its iPSC-Based Cell Therapy Platform at the American Association for Cancer Research (AACR) Annual Meeting 2022

SEATTLE, April 08, 2022 (GLOBE NEWSWIRE) -- Umoja Biopharma, Inc., an oncology company leveraging its proprietary integrated technologies to create next-generation off-the-shelf in vivo (VivoVec)...

Vorherige Seite